Stay updated on PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo
Sign up to get notified when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.

Latest updates to the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page
- Check6 days agoChange DetectedThe page’s interface revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a release change to the site software rather than any modification to the study record content.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check42 days agoChange DetectedVersion v3.5.0 has been added and version v3.4.3 has been removed.SummaryDifference0.0%

- Check49 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check78 days agoChange DetectedAdded Revision: v3.4.2; removed the previous funding notice and Revision: v3.4.1.SummaryDifference0.3%

- Check85 days agoChange DetectedA site-wide notice about government funding status was added, advising users to check cc.nih.gov and opm.gov for updates. The page version was updated to Revision: v3.4.1, replacing v3.4.0.SummaryDifference0.3%

Stay in the know with updates to PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.